38 results about "Drug group" patented technology

To accurately perform an audit of a medicine including a plurality of tablets.SOLUTION: A medicine audit device includes: a rotary disc 401 that rotates around a predetermined axis; a camera 501 that images a medicine placed on the rotating rotary disc 401; and an imaging / audit processing part that determines a type or the number of medicines imaged by the camera 501. In this case, for example, the camera 501 continuously images a plurality of medicine groups placed on the rotating rotary disc 401, and the imaging / audit processing part determines a type or the number of individual medicines in the medicine groups.SELECTED DRAWING: Figure 3

The invention provides lignan, and belongs to the technical field of medicines. According to the invention, a compound shown as a formula I and a compound shown as a formula II are extracted, separated and identified from schisandra chinensis oil for the first time, and the compound shown as the formula I and the compound shown as the formula II are superior to a positive drug group arbutin in the aspect of inhibiting generation of melanin of mouse skin melanoma cells (B16F10); an inflammatory factor release inhibition experiment research shows that the compound shown in the formula I and the compound shown in the formula II have relatively good activity in the aspect of inhibiting LPS-induced mouse mononuclear macrophage RAW264.7 from releasing IL-6 and TNF-alpha; in a skin irritation experiment, the schisandra chinensis non-saponifiable matter containing the compound shown in the formula I and the compound shown in the formula II is non-irritant to the skin of a white rabbit, and it is proved that the compound shown in the formula I and the compound shown in the formula II can be applied to preparation of whitening and anti-inflammatory products. Formula I; formula II.

The invention provides a core prescription mining method and system based on improved association and composite clustering, and relates to the technical field of data processing, and the method comprises the steps: carrying out the statistics of the frequency of traditional Chinese medicines in a standardized traditional Chinese medicine data set; calculating a four-degree association rule analysis index of the binary drug group according to the co-occurrence frequency of the binary drug group; in combination with a preset four-degree association rule analysis index threshold value, screening out a plurality of strongly associated binary drug groups from the binary drug groups; performing standardization and vectorization processing on each strong correlation binary drug group, and constructing structured data containing channel tropism attributes and efficacy attributes; clustering the structured data through a four-order chain type composite clustering algorithm, and determining an extended cluster structure; in combination with a traditional Chinese medicine constraint theory, correcting the extended cluster structure, and outputting a traditional Chinese medicine constraint clustering result; and according to a preset core drug screening rule, optimizing the traditional Chinese medicine constraint clustering result, and generating a hierarchical core prescription structure comprising a core layer, an association layer and a special layer.

The invention belongs to the technical field of medicines. The invention relates to a plaster, in particular to a plaster containing anilinoprofen and a composition. The invention provides an externally applied medicine containing anilinoprofen or a composition containing anilinoprofen and iguratimod. Pharmacodynamic studies show that the aniline-ibuprofen single-prescription plaster can treat osteoarthritis (OA) and rheumatoid arthritis (RA), can effectively inhibit arthrocele and volume increase, remarkably reduces the level of proinflammatory factors, and improves the pathological score of joint tissue. After the anilinoprofen and the iguratimod are combined for use, the curative effect is further enhanced, multiple indexes are obviously superior to those of a single drug group, and an obvious synergistic interaction effect is shown. The iguratimod and anilinoprofen compound preparation disclosed by the invention is developed in an external form such as a gel plaster for the first time, an external compound system of anilinoprofen and iguratimod is innovatively constructed, a safe, effective and convenient novel local treatment choice is provided for OA / RA patients, especially people with oral taboo or needing long-term treatment, and the iguratimod and anilinoprofen compound preparation has good clinical transformation potential and application value.

The application discloses a pancreatic cancer immunotherapy drug composition for jointly targeting CD96 and PD-1, relates to the technical field of biological medicine, and comprises an anti-human CD96 blocking antibody and an anti-human PD-1 blocking antibody. By jointly blocking the double immune checkpoints of CD96 and PD-1, the pancreatic cancer immunotherapy drug composition presents a significant synergistic effect compared with single antibody treatment, can effectively enhance the killing activity of T cells on pancreatic cancer cells, reverses the immune suppression microenvironment of pancreatic cancer, and restores the anti-tumor immune response of the body. The in-vivo experimental results show that the drug composition can significantly inhibit the growth of transplanted tumors, reduce the tumor volume and the tumor weight, and the tumor inhibition effect is obviously better than that of a single drug group. The preparation has stable properties and simple administration, and provides a safe and effective new immunotherapy scheme with a conversion application prospect for clinically refractory pancreatic cancer.

The invention relates to a method for establishing a blood-brain barrier organ aging model and an intervention method for the model, and the method comprises the following steps: S1, model preparation: preparing cryopreserved brain microvascular endothelial cells, resuscitating the cryopreserved brain microvascular endothelial cells, preparing a culture bottle containing a culture medium for later use, preparing a culture chip and an inducer, and treating the culture chip and the inducer for later use; s2, cell culture: taking the recovered brain microvascular endothelial cells in S1, inoculating the brain microvascular endothelial cells in a culture bottle, culturing and carrying out cell passage to obtain brain microvascular endothelial cells in a logarithmic phase; s3, constructing a blood-brain barrier, inoculating the brain microvascular endothelial cells in the logarithmic phase obtained in the S2 to a chip, and culturing to obtain a blood-brain barrier model; and S4, constructing an aging model, taking the blood-brain barrier model in S3, and performing injury treatment to obtain the blood-brain barrier organ aging model. A D-galactose drug group is used for successfully inducing the aging injury of the blood-brain barrier organ model, and a reliable in-vitro blood-brain barrier organ aging injury model is provided.

The invention discloses a dampness-clearing sleep-aiding Tibetan foot bathing tablet and a preparation method thereof, and relates to the technical field of traditional Chinese medicine preparations, the dampness-clearing sleep-aiding Tibetan foot bathing tablet is composed of a monarch drug group, a ministerial drug group, an adjuvant drug group, a conductant drug group and an auxiliary material group, and the preparation method comprises the following steps: step 1, crushing; step 2, weighing; step 3, extracting active ingredients; step 4, drying and powdering; step 5, total mixing; step 6, tabletting; step 7, inner packaging; and step 8, external packaging. Through the compatibility of monarch, minister, assistant and guide, the synergistic effect of dampness clearing and sleep aiding is realized, the monarch drug group and the adjuvant drug group synergistically regulate a dampness clearing pathway (AQP4 aquaporin + TRPV1 ion channel), the minister drug group and the guide drug group synergistically enhance the sleep aiding effect (GABA receptor activation + glutamic acid inhibition), and clinical experiments show that after the traditional Chinese medicine composition is used for 4 weeks, the effective rate of improving the dampness symptom reaches 80%, and the curative effect is good. And the sleep quality improvement rate reaches 82%.

The invention discloses a pharmaceutical composition for improving glucose and lipid metabolism disorder by combining N-p-coumaroyl octoamine and rotundine and application of the pharmaceutical composition, and belongs to the field of biological medicine and metabolic disease treatment. In a db / db diabetic mouse model, it is found that NTPC (10 mg / kg) or ROT (10 mg / kg) single drugs can improve hyperglycemia and insulin resistance and reduce blood fat, and low-dosage combination (5 mg / kg of NTPC and 5 mg / kg of ROT) shows the most significant metabolism improvement effect which is obviously better than that of a single drug group. In an in-vitro fatty acid stimulation model, lipid accumulation in cells can be more remarkably reduced through combination of the two drugs, and fatty acid synthesis genes are inhibited.

The present application relates to the technical field of biological medicine, and in particular to a pharmaceutical composition for treating hepatocellular carcinoma and application thereof, wherein the pharmaceutical composition comprises metformin or a pharmaceutically acceptable salt thereof and obeticholic acid or a pharmaceutically acceptable salt thereof, and the weight ratio of the metformin to the obeticholic acid is 1:0.05-0.2. It is found for the first time that the combination of metformin and farnesol X receptor agonist can regulate the AMPK / mTOR pathway and the immune recruitment mediated by CXCL16 in a synergistic manner, inhibit the proliferation of tumor cells, repair the recruitment function of NKT cells in the microenvironment of hepatocellular carcinoma, and realize the dual anti-tumor effect of metabolic inhibition and immune enhancement. Animal experiments show that the tumor inhibition rate of the combination drug group is significantly better than that of the single drug group, and the safety is good.

According to the phenothiazine functional precursor, the photosensitizer and the preparation method of the phenothiazine functional precursor, halogen or thienyl is introduced into R1 and / or R2 sites of a benzophenothiazine structure to serve as heavy atoms on the basis of structure-function relationship research of benzophenothiazine site modification, generation of strong spin-orbital coupling can be promoted, and the photosensitizer has the advantages that the photosensitizer can be used as a photosensitizer; further, intersystem crossing of the phenothiazine photosensitizer from an excited singlet state (S1) to a triplet state (T1) is promoted, so that the photosensitive effects of the phenothiazine functional precursor and the corresponding phenothiazine photosensitizer are effectively improved. Besides, after the phenothiazine photosensitizer is modified by adding a tetrazine group, controllable closing and opening of phenothiazine are realized, so that the dark toxicity of phenothiazine is effectively reduced, the targeting property and the treatment effect of the photosensitizer are improved by accessing a targeting group and a drug group into the phenothiazine photosensitizer, and the phenothiazine photosensitizer has a wide application prospect.

The invention discloses laurel essential oil with anti-aging activity and application of the laurel essential oil. According to the method, laurel essential oil is used for acting on caenorhabditis elegans to verify the aging delaying effect of the caenorhabditis elegans, after the caenorhabditis elegans are counted and subjected to synchronization treatment, a life determination test of the caenorhabditis elegans is carried out, a blank control group, a DMSO solvent group, a positive drug group and a laurel essential oil experimental group are set respectively, a survival curve is drawn, and statistical analysis is carried out. Results show that the lifetime of nematodes in a laurel essential oil treatment group is remarkably prolonged, and the anti-aging effect of the laurel essential oil treatment group is superior to that of a Meanwhile, target function analysis on the laurel essential oil shows that the essential oil regulates and controls senescence-related pathways. The further determination of the effect of monomer components in the laurel essential oil on delaying caenorhabditis elegans aging shows that p-cymene, methyleugenol, ocimene, linalool, sabinene, 4-terpene alcohol, terpinene and linalyl acetate show significant anti-aging activity.

This invention relates to a specific chimeric antigen receptor (CAR) based on a fully human anti-DLL3 single-chain antibody and its applications. The CAR comprises a CD8 signal peptide, a fully human single-chain antibody specific to the human DLL3 antigen, a CD8 transmembrane region, and 41BB and CD3ζ intracellular signal transduction domains sequentially connected in series. This invention provides immune cells modified with a human DLL3 chimeric antigen receptor by constructing and screening different DLL3 antigen-specific humanized single-chain antibodies, which can specifically bind to the human DLL3 antigen. In in vitro and in vivo killing experiments on human DLL3 antigen-positive tumor models, the CAR-T cells targeting the human DLL3 antigen of this invention significantly and specifically killed human DLL3-positive small cell lung cancer (SCLC) cell lines. Animal model experiments show that after administration of the preferred DLL3 CAR-T cells of this invention, the various drug groups showed significant efficacy, with tumor inhibition rates ranging from 25% to 97%.

The application relates to the field of medicine, in particular to the application of 4-hydroxyphenylacetic acid and irinotecan as cancer chemotherapy drugs. In view of the technical defects that the existing irinotecan chemotherapy hepatoprotective drugs have single action and may interfere with the chemotherapy effect, the application provides the application of 4-hydroxyphenylacetic acid and irinotecan in the preparation of cancer chemotherapy drugs. The application has the following advantages: 1. clear hepatoprotective effect: 4HPAA can significantly alleviate the liver fatty degeneration induced by irinotecan; 2. significant synergistic anti-tumor effect: the tumor inhibition effect of the combination of 4HPAA and irinotecan is significantly better than that of the single-drug group; 3. high safety; and 4. great clinical transformation potential.

The invention relates to the technical field of information visualization and visual analysis, and discloses a graph neural network-oriented prediction result interpretation visualization method, which comprises the following steps: acquiring and processing drug and protein related data, converting the data into a knowledge graph form, and storing the data in a graph database; performing view design, including a projection-based drug aggregation view, a drug target view, a directed acyclic graph-based drug action path view, a path comparison view and a multi-panel-based drug grouping result view, and performing visual layout and implementation respectively. According to the method, in visualization of drug interaction prediction, important features influencing model prediction can be identified, and an interaction path between drugs and a potential biological mechanism thereof are further disclosed, so that the defect that an existing method is insufficient in interpretation capability is overcome; and by constructing an interactive visual view, the credibility of the user on the model prediction result is improved.

The present application relates to the technical field of intelligent control of veterinary drug storage, and discloses a veterinary drug shelf life intelligent early warning control method and system, the method comprising: collecting the real-time storage environment of the target veterinary drug, synchronously monitoring the health abnormal state of livestock and poultry in the target farm; matching the standard storage environment of the veterinary drug, calculating the environmental deviation, and dynamically adjusting the veterinary drug shelf life warning time accordingly; combining the veterinary drug emergency consumption rate corresponding to the health abnormality of the farm, and secondarily optimizing to obtain the emergency warning time. At the same time, the historical use records of the veterinary drug are called, the associated drug group with the highest compatibility and use frequency is screened, the coordination warning time is calculated based on the emergency warning time; the near-expiration drug is selected from the drug group, the drug distribution control is carried out combined with the warehouse location data and the remaining warning time, and the coordination warning time of the associated drug group is updated in real time according to the distribution result. The present application solves the industry problems of low precision of existing veterinary drug shelf life static warning, lack of drug collaborative control, and disconnection of storage and distribution.

The invention relates to the technical field of functional food, and discloses liqueur capable of regulating spleen and stomach, benefiting qi and nourishing blood and a preparation method of the liqueur. The liqueur is prepared from the following raw materials in parts by weight: 25-40 parts of a monarch drug group; 20-35 parts of a ministerial drug group; 15-25 parts of an adjuvant group; 5-10 parts of a conductant drug group; 10-20 parts of a flavor raw material group; 800 to 1500 parts of main body base liquor; the biotransformation strain is added according to 1-3% of the dry weight of the raw materials of the monarch drug group. Firstly, raw materials of the monarch drug group are subjected to biotransformation treatment; performing graded synergistic extraction according to properties of different raw materials to obtain functional mother liquor, blended mother liquor and flavor base liquor; and finally, stably fusing the functional mother liquor and the blended mother liquor with the main base liquor, and aging to obtain a finished product. According to the invention, the bioavailability of core functional components is improved through biotransformation, the physical stability of the product is improved through fractional extraction and step-by-step fusion processes, and the wine body is harmonious in flavor and excellent in sensory quality.

The invention discloses a method for analyzing an anti-inflammatory mechanism of total flavonoids of abelmoschus manihot based on UHPLC-QTOF-MS (Ultra High Performance Liquid Chromatography-Quantitative Time of Flight Mass Spectrometry) cell metabonomics. The method comprises the following steps: optimizing extraction conditions of a metabonomics intracellular sample, inducing RAW 264.7 cells by utilizing lipopolysaccharide (LPS) to construct an inflammation model, extracting the intracellular sample by adopting an optimized extraction mode, and then separating and identifying intracellular metabolites of a control group, a model group and an administration group (medium, low and high TFA (total flavonoids of abelmoschus manihot) dosage groups) by utilizing a UHPLC-Q-TOF-MS (Ultra High Performance Liquid Chromatography-Quantitative Time of Flight Mass Spectrometry) method. Analyzing the obtained secondary mass spectrum data, screening out differential compounds in the three groups by utilizing multivariate variable statistical analysis, and identifying the differential compounds; metaboAnalyst 6.0 is used for carrying out enrichment analysis and metabolic pathway analysis on the screened differential metabolites, and the possible anti-inflammatory activity mechanism of the differential metabolites influencing the total flavonoids of the abelmoschus manihot is clarified. The invention provides an effective metabonomics analysis method for illuminating an anti-inflammatory activity mechanism of the total flavonoids of the abelmoschus manihot flowers.

The invention belongs to the technical field of biological medicines, and particularly relates to application of daptomycin in preparation of a non-small cell lung cancer EGFR-TKI drug resistance reversal agent. The invention discloses that daptomycin can effectively reverse drug resistance for the first time: in-vitro experiments show that evaluation is performed by adopting an HSA model of SynergyFinder software, and it is found that the drug combination synergy score of daptomycin and osimertinib in H1975 drug-resistant cells is 18.166, which indicates that daptomycin and osimertinib have a strong synergistic effect, and the drug resistance of daptomycin and osimertinib can be effectively reversed. Cloning formation experiments show that the cell proliferation inhibition rate of a drug combination group is increased by more than 80% compared with that of a single drug group, and a strong synergistic effect is achieved. An in-vivo experiment further verifies that the tumor volume of a combined drug group is reduced by about 80% compared with that of an osimertinib single drug group, the tumor weight is obviously reduced, drug-resistant relapse does not occur in a treatment period of 22 days, and meanwhile, the stability of the weight of a mouse shows that the safety is good. The invention provides a combined treatment scheme with high efficiency and safety for overcoming EGFR-TKI drug resistance, and has important clinical transformation value.

The invention provides a traditional Chinese medicine anti-brain tumor recombinant prescription and a preparation process and application thereof.The prescription is composed of 12 traditional Chinese medicines including oldenlandia diffusa, sculellaria barbata, paris polyphylla and the like and is divided into a monarch drug group, a ministerial drug group, an adjuvant drug group and a conductant drug group, animal drugs with toxicity or low bioavailability in a traditional prescription are removed, and active peptide nanoparticles replace centipedes, scorpions and the like. The preparation process comprises the following steps: directional extraction of active ingredients (supercritical CO2 extraction, subcritical water extraction and ultrasonic-assisted alcohol extraction), construction of a nano-composite delivery system (bionic exosome loading and bioactive peptide PLGA nanoparticle preparation) and preparation forming, and tablets, freeze-dried powder or injection can be prepared. The prescription can effectively penetrate through the blood brain barrier, the enrichment degree of the medicine in brain tumor tissue is improved, the anti-brain tumor effect is achieved through multi-target cooperation, the safety is high, the curative effect is remarkable, and the medicine is suitable for treating brain glioma.

This application discloses a method for testing the non-inferiority of a new drug when efficacy data follows a skewed normal distribution. This method tests the non-inferiority of a new drug relative to a standard drug when efficacy data follows a skewed normal distribution, ensuring the reliability of the test results. S1. Acquisition of drug efficacy data in clinical trials: In a three-arm non-inferiority clinical trial, drug efficacy data are acquired from three groups of clinical trial results—the new drug group, the standard drug control group, and the placebo control group—based on drug efficacy indicators. The efficacy data follows a skewed normal distribution. S2. Calculation of the probability of committing a Type I error: In the three-arm non-inferiority hypothesis testing model, the probability of committing a Type I error is calculated using a frequentist method or a Bayesian method on the drug efficacy data from the three groups of trials. The probability of committing a Type I error is the probability of the alternative hypothesis H1 occurring when the null hypothesis H0 is true. S3. Determination of the non-inferiority of the new drug: If the probability of committing a Type I error is greater than a given reference value, the new drug is determined to be non-inferior to the standard drug. The reference value is a pre-given clinically significant threshold value.

The invention relates to the technical field of biological medicine, in particular to application of LNPEP as a therapeutic target to preparation of drugs for treating or screening colon cancer. The invention provides application of LNPEP as a therapeutic target in preparation of a medicine for treating or predicting colon cancer. After the LNPEP is knocked down, the drug resistance of the colon cancer to the FOLFOX treatment scheme is obviously improved. Meanwhile, compared with the NC group, the KD group has no influence on cell proliferation after knocking down the LNPEP. After the LNPEP gene is silenced, the autophagy degree of the cell is activated; compared with a medicine adding group, the influence of gene knock-down is greater. After the autophagy inhibitor is used, drug resistance caused by LNPEP knock-down is reversed, which indicates that LNPEP related drug resistance is associated with autophagy. The invention provides a new treatment strategy and drug selection for clinical treatment of colon cancer, and has important clinical application value and wide market prospect.

This invention discloses a live-cell drug screening method and system based on FRET two-hybrid analysis. Firstly, preliminary experiments are conducted on multi-well plates using cell samples transfected with FRET standard plasmids to determine experimental conditions, including cell seeding density, imaging objective, excitation light intensity, field of view analysis range, and measurement of FRET system calibration parameters. Secondly, live-cell drug screening based on FRET two-hybrid analysis is performed under the preliminary experimental conditions. Cell culture is first performed, and drug and control groups are set up, followed by FRET three-channel imaging to calculate E0. D E A and R c And draw E D -R c Figure and E A -(1 / R) c (Figure); then use E D -R c With E A -(1 / R) c The linearly separated FRET two-hybrid analysis method yielded E Dmax E Amax and N A / N D Data was screened using the saturation index sRatio; finally, the active and potential active substances in the drug group were obtained through a significant difference test. This application enables accurate and rapid quantitative FRET measurement under a wide-field microscope with low magnification, meeting high-throughput requirements and screening for active compounds in live cells.

Antibody-drug conjugates comprising a linker, a linker-drug group, and a hydrophilic group are provided.SOLUTION: A linker for use in improving the solubility of a linker-drug conjugate, wherein the conjugate comprises one or more hydrophobic drug compounds and the linker comprises one or more hydrophilic groups. Also provided is a linker for use in improving the solubility of an antibody drug conjugate (ADC), wherein the ADC comprises one or more hydrophobic drug compounds and the linker comprises one or more hydrophilic groups.SELECTED DRAWING: None

The invention discloses an application of combination of KN93 and doxorubicin in prevention and treatment of tumors and tumor metastasis induced by an environmental pollutant PM2.5. Experiments find that KN93 and doxorubicin are combined as active components for use, growth and proliferation of tumors induced by an environmental pollutant PM2.5 can be remarkably inhibited, the number of pulmonary metastasis nodules is remarkably reduced compared with that of a single drug group, and good synergistic anti-tumor and anti-metastasis effects are shown. Therefore, the KN93 and the doxorubicin can be combined to be used for developing the medicine for preventing or treating the PM2.5-induced tumor and tumor metastasis.

A drug packaging device according to the present invention comprises: a storage unit for temporarily storing a drug before packaging the drug; an image capturing unit that captures an image of the medicament in the storage unit; and a controller that, upon determining that a pre-stored sharing storage condition is satisfied, performs a process in which a first drug group including at least one first drug among a plurality of drugs in the same pack is stored in a first storage unit, and thereafter, causes the imaging unit to image the first drug group; after a second drug group including at least one second drug different from the first drug among the plurality of drugs is stored in the first storage unit after the first drug group has been discharged or in a second storage unit different from the first storage unit, the imaging unit captures an image of the second drug group. The present invention provides a drug packaging device capable of achieving the effects of quickening the drug imaging process, improving the accuracy of determining the number of drugs, and the like.

This invention discloses the preparation and application of a ternary carrier-free injectable hydrogel co-assembled from glycyrrhizic acid, norcantharidin, and copper ions. The hydrogel forms a gel without the addition of excipients and possesses excellent gel material properties such as injectability, thermosensitivity, and stability, making it an ideal anti-tumor drug for clinical application. This hydrogel induces tumor cell apoptosis, copper death, and anti-inflammation, synergistically regulating the tumor microenvironment; combined with laser irradiation to enhance the Fenton-like effect, it achieves chemokinetic therapy of tumors. In the Hepa1-6 hepatocellular carcinoma mouse model, this hydrogel exhibits excellent anti-tumor activity, with significantly better efficacy than individual drug groups. Furthermore, this hydrogel has good biocompatibility and is a novel anti-tumor hydrogel that is simple to prepare, green, and has potential for clinical translation.

Embodiments of the present disclosure relate to the technical field of medical data processing, and particularly relate to a medication information processing method, device, system and equipment. The main steps of the foregoing method include: in response to an audit request of a first prescription including multiple items of medication information initiated by a physician terminal device, obtaining historical medication data of a patient corresponding to the first prescription; when the number of conflict drug groups determined according to a preset knowledge graph, the first prescription and the historical medication data is greater than 1, determining a medication risk value of each conflict drug group according to the obtained drug importance degree data of each conflict drug group, the action intensity data of conflict drug combination and the actual interval data between conflict drugs; determining a comprehensive medication risk value of the first prescription according to the plurality of medication risk values; and feeding back an audit result corresponding to the comprehensive medication risk value to the physician terminal device to release or intercept the first prescription. The foregoing method can improve the audit efficiency and accuracy.

The invention relates to the technical field of pharmacology, in particular to application of ursodesoxychoberberine to preparation of a medicine for preventing and / or relieving and / or treating pulmonary fibrosis. The preparation for preventing and / or relieving and / or treating pulmonary fibrosis is characterized in that the preparation contains ursodesoxychoberberine. The preparation also comprises one or more of a pharmaceutically acceptable carrier, an auxiliary material and an excipient. Dosage forms of the preparation include but are not limited to capsules, particles, tablets, pills, spray, suppositories, aerosols, powder aerosols, patches, oral liquid or injection. The indexes of a low-dose group and a high-dose group of the ursodesoxychoberberine are remarkably improved, the effect of the high-dose group is the best, and particularly, the high-dose group of the ursodesoxychoberberine is remarkably superior to that of a pirfenidone (PFD) positive drug group in the aspect of improving the body weight of a mouse. The results show that the ursodesoxychoberberine has a good development prospect as a candidate drug for resisting pulmonary fibrosis.

The invention discloses a use of a mulberry (Morus alba L.) extract, including a method for treating ulcerative colitis, a method for preventing ulcerative colitis, and a method for reduction in Disease Activity Index, DAI. The use is application of a mulberry extract to the preparation of a product for treating and / or preventing ulcerative colitis. The invention experimentally demonstrated that positive drug group, SZ-A-1, SZ-A-2, SZ-A-3, SZ-A-4 and SZ-A-5 (pretreatment) could each significantly inhibit colonic atrophy in UC model mice, and the effects in SZ-A-2, SZ-A-3 and SZ-A-4 groups are comparable to that in positive drug group, with SZ-A-5 (pretreatment) achieving a superior effect to the positive drug. The mulberry extract of the invention, as a component derived from natural plants, has unique advantages of small toxic and side effects, mild and lasting actions etc.

The invention belongs to the technical field of biological medicines, and particularly relates to application of adriamycin and chlormethazine in preparation of a medicine for treating lung cancer. The invention finds that when the chlormethazine and the adriamycin are combined for use, the chlormethazine can obviously enhance the action effect of the adriamycin on tumor cells, and compared with an adriamycin single drug group and a compound preparation group on a tumor-bearing mouse model, the chlormethazine can effectively inhibit tumor growth and obviously prolong the tumor-bearing survival time of the mouse; therefore, the invention provides the application of the adriamycin and the chlormethazine in preparation of the medicine for treating the lung cancer.